AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38036946
Drug: Ustekinumab (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab (6 mg/kg IV at Week 0, 90 mg SC at Week 8)
Trial: 38037105
Drug: mHealth using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mHealth using cellular-enabled electronic dose monitoring
Trial: 38037108
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of CBD
Trial: 38037749
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy lifestyle intervention
Trial: 38037839
Drug: HS-10352 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HS-10352 at 6 mg QD
Trial: 38037839
Drug: HS-10352 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HS-10352 at 8 mg QD
Trial: 38037839
Drug: HS-10352 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HS-10352 (all doses)
Trial: 38038866
Drug: Ad5-nCoV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad5-nCoV vaccine booster dose
Trial: 38039427
Drug: Canakinumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab (200 mg subcutaneously once every 3 weeks)
Trial: 38039427
Drug: Canakinumab plus
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Canakinumab plus pembrolizumab and chemotherapy
Trial: 38039427
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus pembrolizumab and chemotherapy
Trial: 38039991
Drug: Durvalumab (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (1500 mg intravenously once every 4 weeks) with chemoradiotherapy
Trial: 38040478
Drug: Daily or
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily or event-based oral PrEP (tenofovir disoproxil maleate with emtricitabine)
Trial: 38040875
Drug: Antenatal corticosteroid
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal corticosteroid therapy (ACS)
Trial: 38041148
Drug: online cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: online cognitive behavioural therapy intervention based on the unified protocol
Trial: 38041177
Drug: Hyponatremia (natremia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyponatremia (natremia <135 mmol/L)
Trial: 38041177
Drug: Normal natremia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal natremia (135-145 mmol/L)
Trial: 38041177
Drug: Hypernatremia (natremia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypernatremia (natremia >145 mmol/L)
Trial: 38042412
Drug: 7.5 g
RxNorm normalized name: glucose 15 GM per 37.5 GM Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 g GOS/FOS + iron
Trial: 38042412
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g GOS/FOS + iron
Trial: 38042525
Drug: Osimertinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib plus platinum-pemetrexed (combination)
Trial: 38042773
Drug: Robot for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot for medication management
Trial: 38042801
Drug: BUP-XR 300-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUP-XR 300-mg maintenance dose
Trial: 38042801
Drug: BUP-XR 100-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUP-XR 100-mg maintenance dose
Trial: 38042801
Drug: BUP-XR 100-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUP-XR 100-mg and 300-mg maintenance doses
Trial: 38042811
Drug: Daily respiratory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily respiratory exercises
Trial: 38042851
Drug: Olipudase alfa
RxNorm normalized name: OLIPUDASE ALFA
DrugBank: Olipudase alfa (DB12835)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olipudase alfa treatment for 2 years
Trial: 38042851
Drug: Cross-over group
RxNorm normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cross-over group after 1 year of olipudase alfa treatment
Trial: 38043867
Drug: Daytime home
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daytime home parenteral nutrition (HPN)
Trial: 38043867
Drug: Overnight home
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overnight home parenteral nutrition (HPN)
Trial: 38043911
Drug: Minocycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline (100 mg, twice daily)
Trial: 38044460
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) Tranexamic acid (TXA)
Trial: 38044460
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) Tranexamic acid (TXA)
Trial: 38045803
Drug: Monthly BUP-XR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly BUP-XR (Sublocade;® two injections of 300 mg, then four maintenance injections of 100 mg or 300 mg) for 24 weeks
Trial: 38045803
Drug: Daily standard-of-care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily standard-of-care (SoC) medication (liquid methadone 60-120 mg or sublingual/transmucosal buprenorphine 8-24 mg) for 24 weeks
Trial: 38045803
Drug: BUP-XR among
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUP-XR among participants in maintenance treatment for more than 28 days
Trial: 38046839
Drug: High flow
RxNorm normalized name: Blood Set High Flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High flow nasal catheter therapy
Trial: 38046981
Drug: Aclidinium bromide
RxNorm normalized name: Aclidinium Bromide
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Aclidinium bromide 400 µg administered via dry powder inhaler, single and multiple (twice daily) doses.
Trial: 38047142
Drug: Methadone (0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (0.10 mg/kg to 0.20 mg/kg)
Trial: 38047249
Drug: SNG100 cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SNG100 cream (hydrocortisone 1% in a cream base with sulphated polysaccharide), applied twice daily for 14 days
Trial: 38047249
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate 0.1% cream, applied once daily for 14 days
Trial: 38047249
Drug: Hydrocortisone 1%
RxNorm normalized name: HYDROCORTISONE 1% OINT
DrugBank: Hydrocortisone acetate (DB14539)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 1% cream, applied twice daily for 14 days
Trial: 38047249
Drug: SNG100 cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SNG100 cream
Trial: 38048045
Drug: 177Lu-DOTATATE at
RxNorm normalized name: 177Lu-dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 177Lu-DOTATATE at a dose of 7.4 GBq (200 mCi) every eight weeks for four cycles
Trial: 38048133
Drug: Thiazide-type diuretic
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazide-type diuretic
Trial: 38048134
Drug: Cilostazol, 50
RxNorm normalized name: Cilostazol, 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol, 50 mg twice daily for up to 96 weeks
Trial: 38048134
Drug: Placebo, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 1 tablet twice daily for up to 96 weeks
Trial: 38048188
Drug: Intravenous levothyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous levothyroxine (30 μg per hour for a minimum of 12 hours)
Trial: 38048188
Drug: Intravenous levothyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous levothyroxine
Trial: 38048786
Drug: Imetelstat 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imetelstat 7.5 mg/kg administered as a 2-h intravenous infusion every 4 weeks until disease progression, unacceptable toxic effects, or withdrawal of consent.
Trial: 38048786
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as a 2-h intravenous infusion every 4 weeks until disease progression, unacceptable toxic effects, or withdrawal of consent.
Trial: 38048793
Drug: Atezolizumab plus
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab plus standard therapy (cisplatin 50 mg/m2)
Trial: 38048793
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (cisplatin 50 mg/m2)
Trial: 38048799
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (oral dose of 14,000 IU/week)
Trial: 38048802
Drug: Neoadjuvant chemo-immunotherapy
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemo-immunotherapy with camrelizumab (one cycle of priming doublet chemotherapy at 75-80 mg/m2)
Trial: 38048802
Drug: Neoadjuvant chemo-immunotherapy
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemo-immunotherapy with camrelizumab
Trial: 38049197
Drug: Brivaracetam (BRV)
DrugBank: Brivaracetam (DB05541)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Brivaracetam (BRV) 0.5 mg/kg intravenously (IV) twice daily (b.i.d)
Trial: 38049523
Drug: Intracranial injection
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracranial injection of poly(I:C)
Trial: 38049783
Drug: Chemoradiation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiation therapy (CRT)
Trial: 38049955
Drug: EDV add-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDV add-on treatment to TAU (intravenous infusion with 30 mg of EDV twice per day)
Trial: 38049955
Drug: NGF add-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGF add-on treatment to TAU (intramuscular injection of 20 μg of NGF per day)
Trial: 38049955
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU: a combination of intramuscular injections of thiamine, intravenous infusions of other B vitamins with vitamin C and oral medication with vitamin E per day)
Trial: 38049955
Drug: EDV add-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDV add-on treatment to TAU
Trial: 38050737
Drug: CA19-9-normal subgroup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA19-9-normal subgroup (≤37 U/mL)
Trial: 38050737
Drug: CA19-9-high subgroup
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA19-9-high subgroup (>37 U/mL)
Trial: 38051008
Drug: EnhanceFitness (EF)
RxNorm normalized name: Klor-Con/EF
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EnhanceFitness (EF) physical activity intervention, 12-week duration, thrice weekly classes
Trial: 38051292
Drug: Not using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not using hormone therapy
Trial: 38051328
Drug: Sintilimab plus
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab plus chemotherapy (capecitabine and oxaliplatin, XELOX regimen)
Trial: 38051328
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus chemotherapy (capecitabine and oxaliplatin, XELOX regimen)
Trial: 38051699
Drug: Daily SMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily SMS reminders for TB patients and notifications to social supporters for 3 months, then triggered by late or missed dosing for 3 months.
Trial: 38051699
Drug: Weekly SMS
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly SMS reminders for TB patients and notifications to social supporters for 3 months, then triggered by late or missed dosing for 3 months.
Trial: 38051700
Drug: Enhanced vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced vitamin supplement
Trial: 38051700
Drug: Standard vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard vitamin supplement (control)
Trial: 38051723
Drug: Action Observation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Action Observation Therapy (AOT) combined with exercise (balance, strengthening, and mobility exercises guided by 15-minute action observation videos before a 45-minute exercise session)
Trial: 38051750
Drug: Peposertib 50-250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peposertib 50-250 mg once daily plus capecitabine 825 mg/m2 twice daily and radiotherapy 5 days per week
Trial: 38051750
Drug: Peposertib 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peposertib 100 mg cohort
Trial: 38051750
Drug: Peposertib ≤150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peposertib ≤150 mg once daily
Trial: 38052042
Drug: Teclistamab 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teclistamab 1.5 mg/kg subcutaneously once weekly
Trial: 38052302
Drug: Protein-rich oral
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-rich oral nutritional supplement for 4 weeks before TAVR with home-based supervised exercise sessions for 12 weeks after TAVR
Trial: 38052851
Drug: PEDF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEDF treatment of human skin fibroblast (HSF) cell lines with different concentrations and durations.
Trial: 38053101
Drug: Attitudes toward
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Attitudes toward drugs measured by the Drug Attitude Inventory (DAI-10) at baseline
Trial: 38053122
Drug: Group Brief
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Brief Cognitive Behavioral Therapy (G-BCBT)
Trial: 38053122
Drug: Dialectical Behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical Behavior Therapy (DBT) Skills Group
Trial: 38053197
Drug: Low-level light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level light therapy
Trial: 38053196
Drug: Tauroursodeoxycholic acid
RxNorm normalized name: tauroursodeoxycholic acid
DrugBank: Tauroursodeoxycholic acid (DB08834)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tauroursodeoxycholic acid (TUDCA) as add-on therapy to riluzole
Trial: 38053515
Drug: Once-daily somatropin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily somatropin
Trial: 38053657
Drug: H-IGRT (hypofractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H-IGRT (hypofractionated 15 fractions/3 weeks image-guided radiation therapy)
Trial: 38053657
Drug: CRT (normofractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRT (normofractionated 25-33 fractions/5-7 weeks conventional radiation therapy)
Trial: 38053659
Drug: Hypofractionated radiotherapy
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated radiotherapy (25-40 Gy/5 Fx for cohort A; 15-30 Gy/5 Fx for cohort B), chemotherapy, toripalimab, and stereotactic ablative radiotherapy (SABR) for all metastatic lesions.
Trial: 38054696
Drug: JX11502MA 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JX11502MA 0.25 mg
Trial: 38054696
Drug: JX11502MA 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JX11502MA 0.5 mg
Trial: 38054696
Drug: JX11502MA 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JX11502MA 1 mg
Trial: 38054696
Drug: JX11502MA 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JX11502MA 2 mg
Trial: 38054696
Drug: JX11502MA 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JX11502MA 3 mg
Trial: 38054696
Drug: JX11502MA 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JX11502MA 6 mg
Trial: 38054696
Drug: JX11502MA 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JX11502MA 8 mg
Trial: 38055176
Drug: Dual-pathway inhibition
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-pathway inhibition (DPI) with rivaroxaban and low-dose aspirin
Trial: 38055186
Drug: Oral treprostinil
RxNorm normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral treprostinil after clinical worsening
Trial: 38055186
Drug: Placebo followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo followed by oral treprostinil after clinical worsening
Trial: 38055237
Drug: Telemonitoring strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemonitoring strategy (4 daily SMS messages)
Trial: 38055242
Drug: RGRN-305, 250-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RGRN-305, 250-mg tablet, once daily for 16 weeks
Trial: 38055242
Drug: Placebo, matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, matching tablet, once daily for 16 weeks
Trial: 38055253
Drug: Mirvetuximab soravtansine
RxNorm normalized name: MIRVETUXIMAB SORAVTANSINE
DrugBank: Mirvetuximab soravtansine (DB12489)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirvetuximab soravtansine (MIRV) 6 mg/kg every 3 weeks
Trial: 38055253
Drug: Chemotherapy (paclitaxel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan)
Trial: 38055353
Drug: MR-guided stereotactic
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR-guided stereotactic body radiation therapy (SBRT) with 40 Gy prescribed to 95% of the PTV in over five fractions
Trial: 38056770
Drug: Decision support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decision support tool for managing oral anticoagulation (visualized in intervention centers)
Trial: 38056900
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiation therapy (SBRT) combined with adenosine pathway inhibitor oleclumab and neo-adjuvant immuno-chemotherapy (paclitaxel, doxorubicin/cyclophosphamide, durvalumab)
Trial: 38057377
Drug: BIS group
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIS group (10 mg/kg/h propofol infusion adjusted to keep the BIS value between 40 and 60)
Trial: 38057377
Drug: Bolus group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus group (0.5 mg/kg of propofol when necessary)
Trial: 38057636
Drug: Cipaglucosidase alfa
RxNorm normalized name: Cipaglucosidase alfa
DrugBank: Cipaglucosidase alfa (DB16708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cipaglucosidase alfa plus miglustat (20 mg/kg intravenous-infused cipa plus 260 mg oral mig biweekly)
Trial: 38057695
Drug: Epidural nalbuphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural nalbuphine (2 ml, 10 mg)
Trial: 38057695
Drug: Epidural dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural dexmedetomidine (2 ml, 100 µg)
Trial: 38057695
Drug: Epidural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bupivacaine (10 ml 0.25% + 2 ml normal saline)
Trial: 38057772
Drug: LXI-15029, 110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LXI-15029, 110 mg BID (maximum tolerated dose)
Trial: 38057844
Drug: Vildagliptin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin (50 mg tablet) with iftar meal during Ramadan
Trial: 38057875
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg pantoprazole intravenously
Trial: 38057919
Drug: HepB3 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HepB3 vaccine
Trial: 38058646
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy program using elastic bands (16 sessions, 45 minutes each)
Trial: 38058795
Drug: Semaglutide 0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide 0.1, 0.2, or 0.4 mg
Trial: 38059202
Drug: Intradermal acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal acupuncture (IA) at gallbladder meridian acupoint (GBA)
Trial: 38059202
Drug: Intradermal acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal acupuncture (IA) at non-acupoint (NA)
Trial: 38059497
Drug: Arfolitixorin (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arfolitixorin (120 mg/m2 given as two intravenous bolus doses of 60 mg/m2)
Trial: 38059497
Drug: Leucovorin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucovorin (400 mg/m2 given as a single intravenous infusion)
Trial: 38059635
Drug: Oral ceftibuten
RxNorm normalized name: Ceftibuten
DrugBank: Ceftibuten (DB01415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ceftibuten
Trial: 38059946
Drug: 0.60 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.60 g/kg alcohol during late follicular phase (E2 elevated)
Trial: 38060092
Drug: Fast-eluting implant
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast-eluting implant (n = 51)
Trial: 38060092
Drug: Slow-eluting implant
RxNorm normalized name: Slow-Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-eluting implant (n = 54)
Trial: 38060195
Drug: Omission of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omission of radiotherapy with endocrine therapy for 5 years
Trial: 38060199
Drug: Triplet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triplet therapy (atezolizumab 840 mg, ipatasertib 400 mg/day, paclitaxel 80 mg/m2 or nab-paclitaxel 100 mg/m2)